Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$38.97 USD
+0.43 (1.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.98 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BHVN 38.97 +0.43(1.12%)
Will BHVN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHVN
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View
Other News for BHVN
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
3 Biotech Stocks to Buy on the Dip: April 2024
Biotech Alert: Searches spiking for these stocks today
Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)
RBC Capital Keeps Their Buy Rating on Biohaven Ltd. (BHVN)